|
I will not be able to attend tomorrow’s
WG as I will be on holiday – apologies. ·
Regarding
the currency elements within dividendConditions, I missed the last couple of
discussions but my understanding is that so long as SettlementCurrency and
IssuerPaymentCurrency values are added to the determinationMethod, the cases
where the dividend settlement currency is different from either the reference
currency or the main settlement currency will be covered. I have had some communications
with Irena recently regarding this. (However, where determinationMethod is used
as is, the fact that dividend settlement currency is being specified here can
only be deduced from the value, not from the structure or element name – potentially the meaning of the element morphs
at run-time? I don’t currently see it as a big issue.) ·
As for MEIA/MEIA
II, further to James’s comment in recent private email communication to Andrew,
I am happy to make my previously provisional/private FpML suggestion an
official proposal – it’s only a minor tweak. ·
As for the
MCA and MCA Annex issue, I have not had a chance to examine Irena’s email
but I assume it is still in progress? Regards, Takeo From: * Telephone Conference US: 1 888 481 3032 Intl: 1 617 801 9600 Participant code: 8682747 * Agenda 1. Action items from our last meeting 14:00 LDN Fri 06 Nov 2009 All feedback on usage of ( curreny instance, currency reference,
determination method ) IY add Venkat Krishnamurthy as an Observer for Oracle to the email
group IY add values SettlementCurrency and IssuerPaymentCurrency to
determination-method coding scheme IY obtain from CA and ISDA legal 1. Annex publication dates 2. All valid pairs of MCA and MCA Annex 2. ISDA Legal Drafting Progress, implications for FpML 3. NY Fed OTC Commitments Discussion 4. Actions for the remainder of 2009 Schedule any urgent actions, agree meeting times for remainder of this
year 5. AOB This communication is for informational purposes only. It is not intended as an offer or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction. All market prices, data and other information are not warranted as to completeness or accuracy and are subject to change without notice. Any comments or statements made herein do not necessarily reflect those of JPMorgan Chase & Co., its subsidiaries and affiliates. This transmission may contain information that is privileged, confidential, legally privileged, and/or exempt from disclosure under applicable law. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or use of the information contained herein (including any reliance thereon) is STRICTLY PROHIBITED. Although this transmission and any attachments are believed to be free of any virus or other defect that might affect any computer system into which it is received and opened, it is the responsibility of the recipient to ensure that it is virus free and no responsibility is accepted by JPMorgan Chase & Co., its subsidiaries and affiliates, as applicable, for any loss or damage arising in any way from its use. If you received this transmission in error, please immediately contact the sender and destroy the material in its entirety, whether in electronic or hard copy format. Thank you. Please refer to http://www.jpmorgan.com/pages/disclosures for disclosures relating to European legal entities. |